Department Biochemistry of Micronutrients, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558, Nuthetal, Germany,
Genes Nutr. 2007 Dec;2(3):249-56. doi: 10.1007/s12263-007-0055-0. Epub 2007 Oct 16.
Observational studies with healthy persons demonstrated an inverse association of vitamin E with the risk of coronary heart disease or cancer, the outcome of large-scale clinical trials conducted to prove a benefit of vitamin E in the recurrence and/or progression of such disease, however, was disappointing. Vitamin E did not provide benefits to patients with cardiovascular diseases, cancer, diabetes or hypertension. Even harmful events and worsening of pre-existing diseases were reported, which are hard to explain. Since vitamin E is metabolized along the same routes as xenobiotics and induces drug-metabolizing enzymes in rodents, it is hypothesized that a supplementation with high dosages of vitamin E may also lead to an induction of the drug-metabolizing system in patients that depend on drug therapy. Compromising essential therapy might therefore outweigh any benefit of vitamin E in patients. It is recommended to work out at which threshold the drug-metabolizing system can be induced in humans before new trials with high dosages of vitamin E are started.
观察性研究表明，维生素 E 与冠心病或癌症的风险呈负相关，但为了证明维生素 E 对这类疾病的复发和/或进展有益而进行的大规模临床试验的结果却令人失望。维生素 E 并没有给心血管疾病、癌症、糖尿病或高血压患者带来益处。甚至有报道称出现了有害事件和原有疾病的恶化，这很难解释。由于维生素 E 与外源性物质沿着相同的途径代谢，并在啮齿动物中诱导药物代谢酶，因此有人假设，高剂量的维生素 E 补充剂也可能导致依赖药物治疗的患者的药物代谢系统被诱导。因此，在开始新的高剂量维生素 E 试验之前，权衡药物代谢系统在多大程度上被诱导对患者的重要性，可能会超过维生素 E 的任何益处。建议在开始新的高剂量维生素 E 试验之前，确定人类的药物代谢系统在哪个阈值可以被诱导。
